Harpagoside suppresses IL-6 expression in primary human osteoarthritis chondrocytes.

Harpagoside suppresses IL-6 expression in primary human osteoarthritis chondrocytes.

Haseeb Abdul; Ansari Mohammad Yunus; Haqqi Tariq M

Journal of orthopaedic research : official publication of the Orthopaedic Research Society

2017

2017-02

There is growing evidence in support of the involvement of inflammatory response in the pathogenesis of osteoarthritis (OA). Harpagoside, one of the bioactive components of Harpagophytum procumbens (Hp), has been shown to possess anti-inflammatory properties. Here we used an in vitro model of inflammation in OA to investigate the potential of harpagoside to suppress the production of inflammatory cytokines/chemokines such as IL-6 and matrix degrading proteases. We further investigated the likely targets of harpagoside in primary human OA chondrocytes. OA chondrocytes were pre-treated with harpagoside before stimulation with IL-1beta. mRNA expression profile of 92 cytokines/chemokines was determined using TaqMan Human Chemokine PCR Array. Expression levels of selected mRNAs were confirmed using TaqMan assays. Protein levels of IL-6 and MMP-13 were assayed by ELISA and immunoblotting. Total protein levels and phosphorylation of signaling proteins were determined by immunoblotting. Cellular localization of

*c-FOS/AP-1; *harpagoside; *IL-6; *MMP-13; *osteoarthritis; CCAAT-Enhancer-Binding Protein-beta/metabolism; Chemokines/metabolism; Chondrocytes/*drug effects/metabolism; Drug Evaluation; Glycosides/pharmacology/*therapeutic use; Harpagophytum; Humans; Interleukin-1beta; Interleukin-6/antagonists & inhibitors/*metabolism; Matrix Metalloproteinase 13/metabolism; NF-kappa B/metabolism; Osteoarthritis/*drug therapy/metabolism; Phytotherapy; Plant Extracts/pharmacology/therapeutic use; Preclinical; Primary Cell Culture; Proto-Oncogene Proteins c-fos/metabolism; Pyrans/pharmacology/*therapeutic use; Reactive Oxygen Species/metabolism; Transcription Factor AP-1/metabolism

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

311–320

2

35